Home » Chemotherapy
Tag:

Chemotherapy

News

Oncological therapies damage the hearts of survivors – El Financiero

by Dr. Priya Deshmukh - Senior Editor, Health
written by Dr. Priya Deshmukh - Senior Editor, Health

Cancer Treatment’s Silent Threat: Heart Disease Risk Escalates – Urgent Breaking News

The triumph over cancer is often a long and arduous journey, but a growing body of evidence reveals a hidden cost: a significantly increased risk of heart disease. What was once a concern whispered among oncologists is now a recognized pattern, impacting a rising number of survivors and prompting a new field of medicine – cardio-oncology – to emerge. This is breaking news that demands attention, not just for those currently battling cancer, but for anyone interested in the future of healthcare and long-term wellness. This article is optimized for Google News and SEO to deliver the latest information quickly.

A Problem Decades in the Making

Dr. Bogda Koczwara, a Sydney-based oncologist, first observed this troubling connection in the 1990s. A former police officer, successfully treated for non-Hodgkin lymphoma, returned with worsening health. While the cancer was in remission, tests revealed devastating damage to his heart – silent, permanent damage caused by chemotherapy. This case wasn’t an isolated incident. It was an early warning sign of a phenomenon now affecting millions. Modern cancer therapies, while dramatically improving survival rates, are increasingly recognized as potential contributors to cardiovascular disease.

The Rising Tide of Cancer Survivors & Cardiac Complications

The numbers are staggering. Over 18 million cancer survivors in the United States and more than 1.2 million in Australia are living proof of treatment advancements. Europe and Asia are seeing similar increases. But this success comes with a caveat. As patients live longer, they’re experiencing “late effects” – long-term consequences of their treatment, with the cardiovascular system being particularly vulnerable. The very treatments designed to save lives are, in some cases, creating a new health challenge.

Modern Therapies, Modern Risks

Today’s cancer treatments are far more potent than those available just a few decades ago. Immune checkpoint inhibitors, targeted therapies, and drugs that cut off blood supply to tumors are transforming cancer care. However, these advancements aren’t without risk. Immunotherapies can cause heart inflammation (though rare, it’s life-threatening). Medications affecting blood vessels can elevate blood pressure in up to 40% of patients. Targeted therapies can disrupt essential cardiac functions. And the damage often isn’t immediate; it can take years to manifest, making diagnosis difficult.

Cancer Treatment Side Effects on the Heart

Data Confirms the Trend: Heart Disease Deaths on the Rise Among Cancer Survivors

Data from the U.S. Centers for Disease Control and Prevention (CDC) paints a concerning picture. Death certificates listing heart disease as the primary cause, but also indicating a history of cancer, have increased from 4.7 per 100,000 inhabitants in 2019 to 5.5 in 2024. While seemingly modest, experts warn this is an early indicator of a growing problem. Many of these newer oncology medications haven’t been around long enough for their long-term cardiovascular impact to be fully understood.

Cardio-Oncology: A New Field Emerges

Dr. Koczwara, haunted by the fate of his patient, dedicated his career to cancer survivorship and its side effects. He now runs Australia’s first dedicated cancer survivorship center. The medical community is finally responding. Hospitals are establishing specialized cardio-oncology clinics, and researchers are working to identify at-risk patients and develop preventative strategies, including early cardioprotective medication. The cardiac toxicity of anthracyclines, a common chemotherapy drug, was known in the 90s, but the formal field of cardio-oncology was still years away, and the long-term risks weren’t routinely discussed with patients.

Protecting Young Survivors: A Critical Focus

The increasing diagnosis of cancers like leukemia, colorectal cancer, and certain blood cancers in young adults adds another layer of urgency. These survivors face decades of potential cardiovascular risk. Long-term studies show that those who received specific treatments may experience serious heart problems in middle age. Furthermore, pre-existing conditions like obesity, diabetes, and hypertension can amplify the cardiac effects of treatment. Crucially, gaps in follow-up care often occur when patients transition from oncology to primary care.

Virtually all major cancer therapies can leave a mark on the heart, and the effects can be cumulative with multiple treatments. The goal isn’t just cancer remission; it’s ensuring a high quality of life *after* cancer. Cardiovascular risk management is now a central component of post-treatment care, because, increasingly, it’s the heart – not the cancer itself – that will determine a survivor’s long-term well-being.

With information from Bloomberg.

Stay informed with archyde.com for the latest breaking news and in-depth analysis on health, science, and technology. Explore our resources on cancer prevention, heart health, and the evolving landscape of medical care. Don’t miss our upcoming series on proactive health management for cancer survivors – sign up for our newsletter to be notified!

0 comments
0 FacebookTwitterPinterestEmail
Health

Palbociclib Improves Progression‑Free Survival in Double‑Positive Metastatic Breast Cancer: Results from the PATINA Phase 3 Trial

by Dr. Priya Deshmukh - Senior Editor, Health
written by Dr. Priya Deshmukh - Senior Editor, Health

“`html

Palbociclib Extends Progression-Free Survival in Aggressive Breast Cancer, Landmark Study Reveals

Table of Contents

Philadelphia, PA – A groundbreaking clinical trial has demonstrated that adding Palbociclib to standard treatment significantly extends the period before cancer progression in patients battling a notably challenging form of breast cancer. The Phase 3 PATINA study,whose final results were recently published,offers renewed hope for individuals diagnosed with hormone receptor-positive (HR+),human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer.

Understanding the breakthrough

The study,conducted across medical centers in the United States,Europe,New Zealand,and Australia between June 2017 and July 2021,involved 518 patients. researchers found that patients receiving Palbociclib in addition to anti-HER2 therapy and endocrine treatment experienced a median progression-free survival of 44.3 months. This is a substantial improvement compared to the 29.1 months observed in patients receiving anti-HER2 and endocrine therapy alone.

According to Angela M. DeMichele, a co-principal Investigator for the PATINA trial at the University of Pennsylvania, the findings indicate that Palbociclib offers a “substantial and meaningful prolongation of response time and disease control” for patients facing this currently incurable condition. This represents a critical advancement, given the persistent challenges of resistance to existing therapies.

What is HR+/HER2+ Breast Cancer?

Approximately 10 percent of all breast cancers are classified as HR+, HER2+. These cancers often respond well to initial treatment, but frequently develop resistance over time. Current first-line treatment typically involves a combination of chemotherapy with anti-HER2 therapies, followed by longer-term maintenance therapy targeting both HER2 and hormone receptors. The PATINA study focused on improving the effectiveness of this maintenance phase.

How Does Palbociclib Work?

Palbociclib is a CDK4/6 inhibitor,meaning it targets specific proteins that promote cancer cell growth and division. Preclinical and earlier clinical trials suggested that blocking these proteins, even after initial treatment, could help overcome resistance to endocrine and anti-HER2 therapies. The PATINA study is the first large, randomized Phase 3 trial to definitively prove this benefit in this specific patient population.

Key Study Findings at a Glance

Treatment Arm Median Progression-Free Survival Number of Patients
Palbociclib + Anti-HER2 & Endocrine Therapy 44.3 months 261
Anti-HER2 & Endocrine Therapy Alone 29.1 months 257

Collaborative Research Fuels Progress

The PATINA study was a collaborative effort, funded by Pfizer, Inc.,and supported by multiple international research organizations. These included Alliance Foundation trials,Breast Cancer Trials (Australia and New Zealand),Fondazione michelangelo,GBG Forschungs GmbH,PrECOG,SOLTI,and Unicancer. Peter J. O’Dwyer, CEO and chair of PrECOG, emphasized the importance of global partnerships in addressing complex medical challenges.

As of November 2023, the American Cancer Society estimates over 41,500 women and approximately 530 men will die from breast cancer in the United States alone. learn more about breast cancer statistics and support resources.

This study offers a notable step forward in the treatment of a challenging-to-treat cancer. Are new maintenance therapies the future of metastatic breast cancer treatment? And how will these findings impact patient care going forward?

Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is indeed essential to consult with

What improvement in progression‑free survival did palbociclib provide in the PATINA trial for HR+/HER2+ metastatic breast cancer?

Palbociclib & HR+/HER2+ Metastatic Breast Cancer: A Deep Dive into PATINA Trial Results

Metastatic breast cancer, particularly hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) subtypes, presents significant challenges in treatment. The PATINA Phase 3 trial has delivered compelling evidence regarding the efficacy of palbociclib in this patient population, offering renewed hope and improved outcomes. This article breaks down the key findings and their implications for clinical practice.

Understanding HR+/HER2+ Metastatic Breast Cancer

Before delving into the PATINA trial, it’s crucial to understand the characteristics of this specific breast cancer subtype. HR+ cancers grow in response to estrogen or progesterone, while HER2+ cancers have an overabundance of the HER2 protein, promoting cancer cell growth. Approximately 20-30% of metastatic breast cancers are considered double-positive, meaning they express both HR and HER2. Treatment typically involves a combination of hormonal therapy, HER2-targeted therapies (like trastuzumab and pertuzumab), and chemotherapy. Progression-free survival (PFS) – the length of time a patient lives without their cancer growing or spreading – is a primary endpoint in clinical trials evaluating these treatments.

The PATINA Trial: Design and Patient population

The PATINA trial (Palbociclib for Advanced Breast Cancer – NATALIE extension) was a randomized, double-blind, placebo-controlled Phase 3 study. It enrolled 325 pre- or post-menopausal women with HR+/HER2+ metastatic breast cancer who had progressed on prior HER2-targeted therapy. Patients were randomized 1:1 to receive palbociclib plus fulvestrant, or placebo plus fulvestrant.

Key inclusion criteria included:

* Confirmed HR+/HER2+ metastatic breast cancer

* Prior treatment with at least one HER2-targeted agent

* Measurable disease

* Adequate organ function

The primary endpoint was progression-free survival (PFS) assessed by blinded autonomous central review. Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety.

Key Findings: Progression-Free Survival gains

The PATINA trial demonstrated a statistically significant and clinically meaningful improvement in progression-free survival with the addition of palbociclib to fulvestrant.

* Median PFS: Palbociclib + Fulvestrant: 9.2 months vs.Placebo + Fulvestrant: 3.9 months. this represents a hazard ratio (HR) of 0.44 (95% CI, 0.31-0.56; p<0.0001).

* Objective response Rate (ORR): Palbociclib arm showed a higher ORR of 33.1% compared to 11.2% in the placebo arm.

* Duration of Response: Patients in the palbociclib arm experienced a longer duration of response.

These results indicate that palbociclib significantly delays disease progression and improves tumor response in patients with HR+/HER2+ metastatic breast cancer who have already received HER2-targeted therapy.

Safety Profile of Palbociclib

While palbociclib demonstrates significant efficacy, understanding its safety profile is paramount. The most common adverse events observed in the PATINA trial included:

* Neutropenia: A decrease in neutrophil count, increasing the risk of infection.This was the most frequent Grade 3/4 adverse event. Prophylactic granulocyte colony-stimulating factor (G-CSF) support is often utilized.

* Fatigue: A common side effect reported by many patients.

* Nausea: Generally manageable with antiemetic medications.

* Diarrhea: Typically mild to moderate in severity.

* Anemia: A reduction in red blood cell count.

Serious adverse events were generally manageable, and treatment discontinuations due to adverse events were relatively low. Regular monitoring of blood counts is essential during palbociclib treatment.

Real-World Impact and Clinical Considerations

The PATINA trial results have rapidly translated into clinical practice, influencing treatment guidelines for HR+/HER2+ metastatic breast cancer.The combination of palbociclib and fulvestrant is now a standard of care option for patients who have progressed on prior HER2-targeted therapies.

* Biomarker Analysis: While the PATINA trial didn’t mandate specific biomarker testing,ongoing research explores potential biomarkers that may predict response to palbociclib. CDK4/6 expression and Rb protein status are areas of active investigation.

* Treatment Sequencing: Determining the optimal sequencing of therapies – HER2-targeted agents, chemotherapy, CDK4/6 inhibitors – remains an area of ongoing research.

* Patient Monitoring: Close monitoring for neutropenia and other adverse events is crucial to ensure patient safety and optimize treatment outcomes.

Benefits of Palbociclib in Clinical Practice

The integration of palbociclib into treatment regimens offers several key benefits:

* Extended PFS: Provides patients with a longer period without disease progression, improving quality of life.

* Improved Response Rates: Increases the likelihood of tumor shrinkage and symptom control.

* New Treatment Option:

0 comments
0 FacebookTwitterPinterestEmail
Health

Lymphomas, new CAR-T therapy available for those who do not benefit from first-line treatment

by Dr. Priya Deshmukh - Senior Editor, Health
written by Dr. Priya Deshmukh - Senior Editor, Health

Of
V. Mart.

The Italian Medicines Agency has extended the reimbursement of liso-cel to those more “difficult” patients who thus have a greater chance of recovery

One is also available in Italy new therapy for patients with lymphoma who are refractory (i.e. do not respond) to first-line chemo-immunotherapy or who, after finishing it, have a recurrence within 12 months.
The Italian Medicines Agency (Aifa) has, in fact, approved the reimbursement of cell therapy with CAR-T, lisocabtagene maraleucel (liso-cel) for the treatment of adults with diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), Primary mediastinal large B-cell lymphoma (PMBCL) e follicular lymphoma grade 3B (FL3B). These are aggressive pathologies, which often tend to recur and the new treatment has proven to increase the chances of permanent recovery.

Aggressive non-Hodgkin lymphomas

Table of Contents

Diffuse large B-cell lymphoma, the most common form of non-Hodgkin lymphomarepresents approximately 30% of all aggressive lymphomas, which have a more rapid clinical course and require timely treatment. It is a blood cancer characterized by rapid growth of B lymphocytes, a type of white blood cell (immune system cell), which is diagnosed around 13,200 Italians every year.
High-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma (which increasingly occurs in adolescents and young adults), and grade 3B follicular lymphoma are also aggressive forms of non-Hodgkin’s lymphoma. «Lymphomas are treatable and in many cases curable diseases, thanks to availability of numerous therapies which, in recent years, have changed the treatment scenario – he explains Paolo Corradini, professor of Hematology at the University of Milan and director of the Division of Hematology and Bone Marrow Transplant at the IRCCS Foundation National Cancer Institute of Milan -. About 70% of patients with aggressive lymphomas can recover, and people with indolent lymphomas can achieve very long disease-free survival, up to 15 years.”
The approval of this this new CAR-T, lisocabtagene maraleucel, specifically affects those patients who do not benefit from first-line chemo-immunotherapy because it has no effect on their tumor (they are refractory) or because they suffered a relapse quickly.




















































The study: this improves the response of patients

Nello studio TRANSFORM, involving 184 patients with diffuse large B-cell lymphoma, the median event-free survival, after a median follow-up of almost 34 months, reached 29.5 months with liso-cel compared to 2.4 months with standard of careconsisting of chemotherapy followed by autologous transplant. At three years old progression-free survival at 51% compared to 26.5% and overall survival at 63% versus 52%.
Liso-cel has already been available in Italy since June 2024 for patients who have relapsed or are refractory to treatment after two or more lines of systemic therapy. «The extension of the reimbursement of liso-cel by Aifa concerns patients who relapse after the first line: in this way, treatment with cell therapy is brought forward – he clarifies Corradini -. In the TRANSFORM trial, patients with diffuse large B-cell lymphoma treated with liso-cel continue to show improved event-free survival and progression-free survival. Not only that. Improves complete response ratewhich in an aggressive disease such as large B-cell lymphoma is the prerequisite for recovery, was equal to 74% compared to 43%: this increase translates into an improvement in survival”.

A “revolution” in cancer treatment

The CAR-T therapy it is one of the greatest achievements of scientific research and one of the greatest “revolutions” in cancer treatment: has changed in the space of a few years the prospects for patients with blood cancers for whom “there was nothing left to do” (they had failed to achieve results with all other available treatments) and that now they even can heal and get your life back to the fullest. There are several CAR-Ts available todaywhich consist of a genetic modification of the patient’s T lymphocytes, which are induced to eliminate the neoplastic cells once reinfused.
They are part of the so-called advanced therapies and specifically they are therapies partly cell phones, as they use the patient’s T lymphocytes, partly geneticas T lymphocytes are genetically modified.
«CAR-Ts are “chemo-free“, that is, they do not involve use in association with chemotherapy, with important advantages for patients – continues Corradini -. Furthermore, in patients refractory to chemotherapy, CAR-Ts can determine recovery when traditional treatments, such as chemotherapy, transplant or radiotherapy, do not offer advantages. In the TRANSFORM study, liso-cel has proven to be an effective, short-lasting treatment because a single infusion is enough, capable of guaranteeing a good quality of life and an improvement in treatment possibilities”.

«The significant progress made in recent years in the treatment of blood cancers, such as the use of CAR-T therapies, have profoundly changed the therapeutic path of many patients, opening up new perspectives even for those who until recently had limited options – conclude Giuseppe Toro, national president of AIL (Italian Association against Leukemia, Lymphoma and Myeloma) -. In this rapidly evolving scenario, it is essential that patients do not feel alone and can count on care that goes beyond the strictly clinical aspect. The needs of patients with lymphoma are complex and also concern psychological support, access to correct and certified medical information, orientation in treatment paths and constant assistance during all phases of the disease. AIL has always been committed to responding to these needs by offering concrete support through the network of volunteers, more than 17,000 throughout Italy, and the AIL accommodation homes, which allow patients and their families to face treatment with greater serenity, close to hematology centres”.

January 29, 2026

© ALL RIGHTS RESERVED

Do you have a doubt or medical question?

Our doctors and specialists answer your questions on health topics

What are the eligibility criteria for CAR‑T therapy in lymphoma patients?

Lymphomas & Beyond First-Line Treatment: A New CAR-T Therapy option

for individuals battling lymphomas – cancers that originate in the lymphatic system – the treatment journey can be complex. While initial, or first-line, therapies like chemotherapy and radiation often prove effective, a significant number of patients unfortunately experiance relapse or find their disease unresponsive to these standard approaches. Fortunately, advancements in immunotherapy are offering renewed hope, particularly wiht the emergence of new CAR-T cell therapies.

Understanding CAR-T Cell Therapy: A Personalized approach

Chimeric Antigen Receptor (CAR) T-cell therapy isn’t a one-size-fits-all treatment. It’s a highly personalized form of immunotherapy that harnesses the power of your own immune system to fight cancer. Here’s a breakdown of the process:

  1. T-Cell Collection: T cells, a type of white blood cell crucial for immune function, are collected from the patient’s blood. This process, called leukapheresis, is similar to dialysis.
  2. Genetic Modification: In a specialized laboratory, these T cells are genetically engineered to express a CAR. This CAR is designed to recognize a specific protein, or antigen, found on the surface of lymphoma cells. Currently approved CAR-T therapies primarily target the CD19 protein, common in many B-cell lymphomas.
  3. Cell Expansion: The modified CAR T cells are then grown and multiplied in the lab to create a large enough dose for treatment.
  4. Infusion: The expanded CAR T cells are infused back into the patient’s bloodstream. These “re-engineered” cells now actively seek out and destroy lymphoma cells expressing the targeted antigen.

Wich Lymphomas Respond to CAR-T Therapy?

While CAR-T therapy shows promise across various lymphoma subtypes, it’s currently most frequently used for:

* Diffuse Large B-cell Lymphoma (DLBCL): Particularly for patients who have relapsed after, or are refractory to, two or more lines of systemic therapy.

* Follicular Lymphoma (FL): Increasingly used for patients with relapsed/refractory FL, especially those with high-grade transformation.

* Mantle Cell Lymphoma (MCL): Approved CAR-T therapies are available for MCL patients who have tired other treatment options.

* Primary Mediastinal Large B-cell lymphoma (PMLBL): A more aggressive subtype of DLBCL, CAR-T therapy is demonstrating encouraging results.

The eligibility criteria are stringent and depend on the specific CAR-T product and the patient’s overall health. A thorough evaluation by a hematologist-oncologist experienced in cellular therapies is essential.

New Developments: Beyond CD19 Targeting

The field of CAR-T therapy is rapidly evolving. Researchers are actively exploring therapies that target antigens beyond CD19. This is crucial because some lymphomas can develop resistance by losing CD19 expression.

* Dual-Targeting CAR-T Cells: these innovative therapies are engineered to recognize two different antigens simultaneously, reducing the risk of resistance.

* CAR-T Cells Targeting Novel Antigens: Research is focused on identifying and targeting antigens uniquely expressed on lymphoma cells, minimizing off-target effects.

* “Armored” CAR-T cells: These cells are modified to enhance their persistence and effectiveness within the tumor microenvironment, overcoming immunosuppressive factors.

Managing Side Effects: A Critical Component of Care

CAR-T therapy, while powerful, isn’t without potential side effects. These can range from mild to severe and require careful monitoring and management.

* Cytokine Release Syndrome (CRS): A systemic inflammatory response triggered by the activated CAR T cells. Symptoms can include fever, fatigue, nausea, and difficulty breathing.Tocilizumab, a monoclonal antibody, is frequently enough used to manage severe CRS.

* Neurotoxicity: Neurological side effects, such as confusion, seizures, and speech difficulties, can occur. The exact mechanisms are still being investigated.

* B-cell Aplasia: Because many CAR-T therapies target CD19, thay can deplete healthy B cells, leading to temporary immune deficiency. Immunoglobulin replacement therapy might potentially be necessary.

* Infections: Suppressed immune function increases the risk of infections. Prophylactic antibiotics and antiviral medications are often prescribed.

Specialized centers with experience in CAR-T therapy have established protocols for managing these side effects effectively.

Real-world Impact: Patient stories & Emerging Data

The impact of CAR-T therapy is best illustrated through patient experiences. While individual results vary, many patients who have exhausted all other treatment options have achieved complete remission with CAR-T therapy, experiencing a significant improvement in their quality of life.

For example,a retrospective study published in The Lancet Oncology (2024) demonstrated a 54% overall response rate and a 38% complete response rate in patients with relapsed/refractory DLBCL treated with a novel CAR-T product targeting a different antigen than CD19. These findings highlight the potential of expanding CAR-T therapy beyond traditional targets.

Accessing CAR-T Therapy: What to Expect

Accessing CAR-T therapy requires a referral to a certified treatment center. The process involves:

* Comprehensive Evaluation: to determine eligibility and assess overall health.

* Insurance Pre-Authorization: CAR-T therapy is expensive, and pre-authorization from insurance is typically required.

* Leukapheresis & Cell Manufacturing: This process can take several weeks.

* Lymphodepletion: Before CAR T-cell

0 comments
0 FacebookTwitterPinterestEmail
News

[인터뷰] Even lymphoma vaccine…Standard Animal Medical Center Integrated Oncology Center Director Kim Geon-ho and Vice Director Ryu Seong-yong – Daily Bet

by Dr. Priya Deshmukh - Senior Editor, Health
written by Dr. Priya Deshmukh - Senior Editor, Health

Urgent: Korean Veterinary Hospital Leads the Charge in Personalized Pet Cancer Treatment with AI and Novel Vaccines

Seoul, South Korea – In a significant leap forward for veterinary oncology, the Standard Animal Medical Center’s Integrated Oncology Center is making waves with its pioneering use of artificial intelligence and a novel lymphoma vaccine to combat cancer in companion animals. This breaking development offers new hope for pet owners facing the heartbreaking reality of a cancer diagnosis, a disease now affecting nearly a quarter of dogs and cats in Korea.

The Rising Tide of Pet Cancer: A Global Concern

Cancer is the leading cause of death for dogs and cats, accounting for approximately half of all deaths in dogs over 10 years old and 40% in cats. North American statistics echo this grim reality, with tumors being the number one cause of canine mortality. The incidence rate is rapidly increasing, particularly after a pet reaches five years of age. This surge isn’t simply due to pets living longer; it reflects a complex interplay of factors, including genetics, environmental exposures, and improved diagnostic capabilities.

Standard Animal Medical Center: An Integrated Approach

The Standard Animal Medical Center is responding to this challenge with a holistic, “Integrated Oncology Center” model. Founded by Director Kim Geon-ho and Vice Director Ryu Seong-yong, both graduates of Seoul National University College of Veterinary Medicine, the center emphasizes multidisciplinary collaboration between oncologists, surgeons, and radiologists. This collaborative spirit ensures each patient receives a customized treatment plan, addressing not only the tumor itself but also any underlying health conditions that might complicate recovery.

AI-Powered Diagnostics and the Promise of Precision Medicine

One of the most exciting developments at the center is the implementation of AI-based diagnostic analysis. While still in the experimental phase, this technology promises to improve the accuracy and speed of cancer detection, allowing for earlier intervention. This aligns with the growing trend of “patient-tailored precision medicine,” where treatments are specifically designed based on a pet’s individual genetic makeup and tumor characteristics. Director Kim emphasizes the importance of evidence-based treatment, avoiding unnecessary or prolonged therapies.

Lymphoma Vaccine: Boosting the Immune System

Beyond AI, the center is also utilizing the APAVAC® lymphoma vaccine, developed by Hastim in France. This isn’t a preventative vaccine, but a “therapeutic vaccine” designed to stimulate the pet’s own immune system to recognize and attack cancer cells. Clinical trials have shown promising results, with vaccinated lymphoma patients exhibiting significantly longer survival times. This offers a potentially less invasive and more affordable alternative to some of the more aggressive cancer treatments currently available.

Navigating Chemotherapy and Beyond: A Focus on Quality of Life

The team at Standard Animal Medical Center is also refining chemotherapy protocols, advocating for potentially higher dosages (when safely tolerated) and a more cautious approach to antibiotic use. They’ve observed that more severe neutropenia – a common side effect of chemotherapy – can actually correlate with longer survival times, challenging conventional wisdom. However, they stress the importance of carefully managing side effects and prioritizing the patient’s overall quality of life. They also highlight the dangers of administering steroids before a definitive diagnosis, as they can interfere with accurate test results and potentially reduce the effectiveness of chemotherapy.

Looking Ahead: The Future of Veterinary Oncology

The advancements at Standard Animal Medical Center represent a broader shift in veterinary oncology, with a growing emphasis on specialization, research, and collaboration. While immunotherapy remains expensive and largely inaccessible in Korea, the lymphoma vaccine offers a viable alternative. The center’s commitment to sharing its knowledge and experience through academic partnerships and publications promises to accelerate progress in the field. Ultimately, the goal is to provide pets and their owners with the best possible chance at a long and healthy life, even in the face of a cancer diagnosis. The team at Standard Animal Medical Center isn’t just treating cancer; they’re building a future where pets receive the same level of personalized, cutting-edge care as their human counterparts.

For more breaking news and in-depth coverage of veterinary health advancements, stay tuned to archyde.com. We’re committed to bringing you the latest information to help you keep your furry friends happy and healthy.

0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts
@2025 - All Right Reserved.

Hosted by ByoHosting - Most Recommendeed Webhhosting. For complains, abuse, advertising contact:
[email protected]

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.